42 patents
Utility
Fused Heteroaromatic Pyrrolidinones
21 Sep 23
Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
Filed: 12 Jan 23
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
5 Jan 23
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Roland J. Billedeau, Jim Li, Lijing Chen
Filed: 13 May 21
Utility
Ectonucleotidase Inhibitors and Methods of Use Thereof
17 Nov 22
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Lijing CHEN, Roland Joseph BILLEDEAU, Jim LI, Timothy Friend STANTON
Filed: 18 Jun 20
Utility
Fused Heteroaromatic Pyrrolidinones
29 Sep 22
Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
Filed: 21 Jun 19
Utility
Solid state forms of fused heteroaromatic pyrrolidinones
7 Jun 22
Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((1R,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof.
Rongliang Chen, Tomonori Ichibakase, Chunrong Ma, Christopher F. Matthews, Hajime Motoyoshi, Colin O'Bryan, Kentaro Yaji, Naoki Yoshikawa
Filed: 8 May 20
Utility
Arginase inhibitor combination therapies
5 Apr 22
The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.
Amani Makkouk, Matthew I. Gross, Francesco Parlati
Filed: 8 Nov 17
Utility
Ectonucleotidase inhibitors and methods of use thereof
28 Dec 21
The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof.
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Filed: 27 Sep 19
Utility
Combination Therapy with Glutaminase Inhibitors and Immuno-oncology Agents
25 Nov 21
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
Filed: 4 Mar 21
Utility
Ectonucleotidase inhibitors and methods of use thereof
16 Nov 21
The invention relates to novel heterocyclic compounds having CD73 inhibitory activity and pharmaceutical preparations thereof.
Lijing Chen, Jim Li, Eric B. Sjogren, Roland J. Billedeau
Filed: 27 Sep 19
Utility
Heterocyclic Glutaminase Inhibitors
23 Sep 21
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Jim Li, Lijing Chen, Bindu Goyal, Guy Laidig, Timothy F. Stanton, Eric B. Sjogren
Filed: 5 Oct 20
Utility
Compositions and Methods for Inhibiting Arginase Activity
26 Aug 21
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure.
Eric B. SJOGREN, Jim LI, Lijing CHEN, Roland J. BILLEDEAU, Timothy F. STANTON, Michael VAN ZANDT, Darren WHITEHOUSE, Gunnar E. JAGDMANN, JR., Lene Raunkjaer PETERSEN
Filed: 20 Jan 21
Utility
Ectonucleotidase inhibitors and methods of use thereof
3 Aug 21
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Lijing Chen, Roland Joseph Billedeau, Jim Li
Filed: 20 Jun 19
Utility
Conjoint Therapy with Glutaminase Inhibitors
17 Jun 21
The invention relates to methods of treating cancer using novel heterocyclic glutaminase inhibitor compounds conjointly with a PD1 or PD-L1 inhibitor.
Keith Orford
Filed: 1 Nov 18
Utility
Ectonucleotidase inhibitors and methods of use thereof
15 Jun 21
The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof.
Roland J. Billedeau, Jim Li, Lijing Chen
Filed: 19 Dec 19
Utility
Compositions and methods for inhibiting arginase activity
1 Jun 21
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure.
Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
Filed: 14 Feb 20
Utility
Method of Preparing (3R,4S)-3-ACETAMIDO-4-ALLYL-N-(TERT-BUTYL)PYRROLIDINE-3-CARBOXAMIDE
27 May 21
A method is provided to conveniently separate racemic (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide and (3S,4R)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide using selective crystallization with chiral carboxylic acids.
Michael VAN ZANDT, Jennifer L. SAVOY
Filed: 1 Feb 21
Utility
Compositions and Methods for Inhibiting Arginase Activity
18 Mar 21
The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent.
Matthew I. GROSS, Susanne M. STEGGERDA, Weiqun LI
Filed: 19 Nov 20
Utility
Combination therapy with glutaminase inhibitors and immuno-oncology agents
9 Mar 21
The invention relates to methods of treating cancer, myeloproliferative diseases, or immunological or neurological diseases with a combination of a glutaminase inhibitor and an immuno-oncology therapeutic agent, such as an inhibitor of arginase, CTLA-4, indoleamine 2,3-dioxygenase, and/or PD-1/PD-L1.
Susan M. Molineaux, Matthew I. Gross, Susan D. Bromley, Francesco Parlati, Mark K. Bennett
Filed: 1 Feb 19
Utility
Compositions and Methods for Inhibiting Arginase Activity
4 Mar 21
The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention.
Eric B. SJOGREN, Jim LI, Michael VAN ZANDT, Darren WHITEHOUSE
Filed: 12 Nov 20
Utility
Compositions and methods for inhibiting arginase activity
2 Feb 21
The invention relates to methods of treating cancer, with a combination of an arginase inhibitor and a chemotherapeutic agent.
Matthew I. Gross, Susanne M. Steggerda, Weiqun Li
Filed: 29 Jul 19